# Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC

> **NCT03263650** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 96 (actual)

## Conditions studied

- Prostate Cancer Aggressiveness
- Prostate Carcinoma

## Interventions

- **DRUG:** Cabazitaxel
- **DRUG:** Carboplatin
- **DRUG:** Prednisone 5Mg
- **DRUG:** Olaparib

## Key facts

- **NCT ID:** NCT03263650
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-10-03
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2026-02-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03263650

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03263650, "Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03263650. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*